Congress Materials

This section includes select Ascendis Pharma posters and presentations that have been presented at medical or scientific congresses. Congress materials may include information regarding investigational products or uses that have not received FDA approval and therefore safety and efficacy have not been established. Ascendis Pharma does not recommend or endorse using its products in any manner that is inconsistent with FDA-approved labeling. Any author conclusions do not represent the opinions of Ascendis Pharma.

Endocrine Rare Diseases

Disease State

Products

Growth Hormone Deficiency

Safety and Effectiveness of Lonapegsomatropin in the SkybriGHt Registry: Analysis of the First 100 Patients Enrolled With 2 Years of Follow-Up

Long-Term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

Safety and Effectiveness of Lonapegsomatropin in the SkybriGHt Registry Study: Analysis of the First 100 Patients Enrolled With 1 Year of Follow-Up

Results of the foresiGHt Trial Support the Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency

The Majority of Children With Pediatric Growth Hormone Deficiency Treated With Lonapegsomatropin for up to 6 Years Met or Exceeded Average Parental Height SDS: Final Results of enliGHten

Practical Management of Pediatric Growth Hormone Deficiency With Lonapegsomatropin-tcgd

Hypoparathyroidism

Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults With Chronic Hypoparathyroidism: 156-Week Results From the PaTHway Trial

Palopegteriparatide Treatment in Adults With Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial

Five-Year Data Report From the Phase 2 PaTH Forward Trial of Palopegteriparatide for Adults With Hypoparathyroidism

Sustained Improvement in Renal Function With Palopegteriparatide in Adults With Chronic Hypoparathyroidism: Three-Year Results From the PaTH Forward and PaTHway Trials

Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Chronic Hypoparathyroidism: 214-Week Results From the Phase 2 PaTH Forward Trial

Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial

Sustained Improvement in Skeletal Dynamics and Renal Function With Palopegteriparatide in Adults With Chronic Hypoparathyroidism: 2-Year Results From the Phase 3 PaTHway Trial

Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial

Sustained Improvement in Renal Function vith Palopegteriparatide in Adults With Chronic Hypoparathyroidism: 2-Year Results From the Phase 3 PaTHway Trial

TransCon PTH Enables Independence From Conventional Therapy While Maintaining Normal Serum Calcium in Adults With Chronic Postsurgical Hypoparathyroidism: Results From a Sub-Analysis of the PaTHway Phase 3 Trial

Achondroplasia

Continued Improvements in Lower Extremity Alignment in Navepegritide-Treated Children With Achondroplasia: Week 104 Results From the ApproaCH Trial

Effects of Navepegritide and Lonapegsomatropin on Manifestations of Skeletal Dysplasia in Children With Achondroplasia: 52-Week Results From the Phase 2 COACH Trial

Population Pharmacokinetics and Exposure Response Analyses of Navepegritide in Children With Achondroplasia

Navepegritide Combined With Lonapegsomatropin for the Treatment of Children With Achondroplasia: 52-Week Results From the Phase 2 COACH Trial

ApproaCH Trial Open Label Extension: Week 104 Results in Children With Achondroplasia Aged 5 Years or Older Treated With Navepegritide

Growth Outcomes and Safety of Navepegritide in Children With Achondroplasia: Results of the ApproaCH Trial Open-Label Extension

Once-Weekly Lonapegsomatropin (TransCon hGH) Added to Once-Weekly Navepegritide (TransCon CNP) in Children With Achondroplasia: 26-Week Results from the Phase 2 COACH Trial

Improvements in Lower Extremity Alignment are Associated With Physical Functioning in Children With Achondroplasia Treated With Navepegritide: 52-Week Results From the ApproaCH Trial

TransCon CNP (Navepegritide) Improved Physical Functioning in Children With Achondroplasia in the ApproaCH Trial